



Redsense receives first order based on the Consip tender in Italy

Redsense Medical AB (publ) announces that a first order valued at 150 KSEK has been received from the company's Italian business partner Spindial based on the large Consip tender where Spindial was declared one of five winners. The deliveries are now starting and will continue for five years.

Spindial's winning offer was the first in a large public tender where a DBB-EXA dialysis machine from Nikkiso and the Redsense blood leakage alarm was offered together with a direct connection between the systems. This makes it possible to automatically and immediately stop the blood flow, and thus offer superior patient safety that was a major contributing factor to the result in the procurement.

The result in the tender, and the fact that the decision was declared final after a long appealing process, is to be considered a market breakthrough for Redsense.

"The concept Spindial offered was new in a public tender context, but it was still declared one of the winners and took second place in the tender's quality ranking. This says a lot about Spindial's impressive work as well as the products included in their offer. Redsense is now setting a new standard for patient safety during hemodialysis treatments that has received major attention all over Europe. Based on this, Redsense plays a major role in ongoing public tender processes, and the interest in including a direct connection to Redsense in upcoming dialysis machine models from additional manufacturers has increased significantly," says Redsense Medical's CEO Patrik Byhmer.

"It has taken a long time and a lot of hard work to become a winner in this tender, and it is therefore very satisfying to be able to start with the deliveries. We look forward to continue our successful collaboration with Redsense during the delivery process," says Marcello Grondelli, Spindial's CEO.

The Consip tender in Italy covers over 3 million dialysis treatment over 5 years in total.

For more information, please contact
Patrik Byhmer, CEO Redsense Medical AB (publ)
Telephone: +46 (0) 35 - 10 60 30
Email: patrik.byhmer@redsemsemedical.com
Website: www.redsemsemedical.com

About Redsense Medical

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage and minimizing blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. The company has also developed an internationally standardized direct connection enabling compatible dialysis machines to stop the blood flow automatically when blood leakage occurs. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.

Redsense Medical's stock is listed on Nasdaq First North with ticket REDS. Erik Penser Bank is the company's Certified Adviser.

This information is such information that Redsense Medical AB (publ) is obligated to publish in compliance with the EU market abuse regulation. This information was provided, through the above contact, for publication on the 16 of October 2018.